**Author details**

Ulises López-Cardoza, Carles Díez-López and José González-Costello\*

\*Address all correspondence to: jgonzalez@bellvitgehospital.cat

Advanced Heart Failure and Transplant Unit, Heart Disease Institute, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

[3] Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patiens with systolic heat failure and mild symtoms. The New England Journal of Medicine. 2011;**364**:11-21. DOI:

Heart Transplant: Current Indications and Patient Selection

http://dx.doi.org/10.5772/intechopen.75507

29

[4] Jhund PS, Macintyre K, Simpson CR, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: A population study of 5.1 million people. Circulation. 2009;**119**:515-523. DOI: 10.1161/CIRCULATIONAHA.

[5] González-Vílchez F, Gómez-Bueno M, Almenar-Bonet L, et al. Registro español de trasplante Cardiaco. XXVIII Informe Oficial de la Sección de Insuficiencia Cardiaca de la Sociedad Española de Cardiología (1984-2016). Revista Española de Cardiología.

[6] Setoguchi S, Stevenson LW, Schneewelss S. Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal. 2007;**154**:260-

[7] Roig-Minguell E, Pérez-Villa F, Castel-Lavilla MA. Estudio y selección del receptor de trasplante cardiaco. In: Trasplante cardiaco. 1st ed. Pulpon LA, Crespo Leiro MG, edi-

[8] Gulati A, Jabbour A, Ismali TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. Journal of the

[9] Radenkovic D, Weingärtner S, Ricketts L. T1 mapping in cardiac MRI. Heart Failure

[10] Pinto YM et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal. 2016;**14-**37(23):1850-1858. DOI: 10.1093/eurheartj/ehv727. Epub 2016 Jan 19 [11] Hershberger RE, Morales A, Siegfried JD. Clinical and genetic issues in dilated cardiomyopathy: A review for genetics professionals. Genetics in Medicine. 2010;**12**:655-667.

[12] Captur G et al. Lamin and Heart. Heart. 2018;**104**(6):468-479. DOI: 10.1136/heartjnl-

[13] Bermúdez-Jiménez FJ, et al. The novel desmin mutation p.Glu401Asp impairs filament formation, disrupts cell membrane integrity and causes severe arrhythmogenic left ventricular cardiomyopathy/dysplasia. Circulation. 2017;**137**(15):1595-1610. DOI: 10.1161/

[14] Ortiz-Genga MF et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. Journal of the American College of Cardiology.

American Medical Association. 2013;**309**:896-908. DOI: 10.1001/jama.2013.1363

tors. Buenos Aires: Editorial Médica Panamericana; 2009. 15-30 p

Reviews. 2017;**22**:415-430. DOI: 10.1007/s10741-017-9627-2

2017;**70**:1098-1109. DOI: 10.106/j.recesp.2017.07.032

266. DOI: 10.1016/j.ahj.2007.01.041

DOI: 10.1097/GIM.0b013e3181f2481f

CIRCULATIONAHA.117.028719

2016;**68**(22):2440-2451. DOI: 10.1016/j.jacc.2016.09.927

2017-312338

10.1056/NEJMoa1009492

108.812172
